View Post

The Long-Term Impact of Hormone Therapy on Breast Cancer Risk

In Clinical Studies News by Barbara Jacoby

By: Zuzanna Walter From: worldhealth.net For several decades, hormone therapy and its risk-to-benefit ratio have been a controversial topic within the scientific community. First published in 2002, reports from the Women’s Health Initiative (WHI) presented data on the complicated benefits and potential adverse events associated with menopausal hormone therapy. Prior to this, estrogen therapy was put into question due to …

View Post

High-Dose Chemo Most Benefits Patients With High-Risk Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Maggie L. Shaw From: ajmc.com A 20-year follow-up comprising a secondary analysis to an original study shows that high-dose chemotherapy plus hematopoietic stem cell transplant benefit patients with high-risk stage III disease with 10 or more axillary lymph nodes involved. Adjuvant high-dose chemotherapy (HDCT) with cyclophosphamide/thiotepa/carboplatin plus hematopoietic stem cell transplant (HSCT), compared with conventional-dose chemotherapy (CDCT), was shown …